These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial. Murphy RJ; Godfrey K; Shaw AD; Muthukumaraswamy S; Sumner RL BMC Neurosci; 2024 Feb; 25(1):7. PubMed ID: 38317077 [TBL] [Abstract][Full Text] [Related]
4. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617 [TBL] [Abstract][Full Text] [Related]
5. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Anderson T; Petranker R; Rosenbaum D; Weissman CR; Dinh-Williams LA; Hui K; Hapke E; Farb NAS Psychopharmacology (Berl); 2019 Feb; 236(2):731-740. PubMed ID: 30604183 [TBL] [Abstract][Full Text] [Related]
13. Microdosing psychedelics: Motivations, subjective effects and harm reduction. Lea T; Amada N; Jungaberle H; Schecke H; Klein M Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967 [TBL] [Abstract][Full Text] [Related]
14. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231 [TBL] [Abstract][Full Text] [Related]
15. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study. de Wit H; Molla HM; Bershad A; Bremmer M; Lee R Addict Biol; 2022 Mar; 27(2):e13143. PubMed ID: 35106880 [TBL] [Abstract][Full Text] [Related]
17. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Murray CH; Tare I; Perry CM; Malina M; Lee R; de Wit H Psychopharmacology (Berl); 2022 Jun; 239(6):1735-1747. PubMed ID: 34613430 [TBL] [Abstract][Full Text] [Related]
18. An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1). Donegan CJ; Daldegan-Bueno D; Sumner R; Menkes D; Evans W; Hoeh N; Sundram F; Reynolds L; Ponton R; Cavadino A; Smith T; Roop P; Allen N; Abeysinghe B; Svirskis D; Forsyth A; Bansal M; Muthukumaraswamy S Pilot Feasibility Stud; 2023 Oct; 9(1):169. PubMed ID: 37798662 [TBL] [Abstract][Full Text] [Related]
19. Psychedelic microdosing benefits and challenges: an empirical codebook. Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862 [TBL] [Abstract][Full Text] [Related]
20. Motives and Side-Effects of Microdosing With Psychedelics Among Users. Hutten NRPW; Mason NL; Dolder PC; Kuypers KPC Int J Neuropsychopharmacol; 2019 Jul; 22(7):426-434. PubMed ID: 31152167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]